MicuRx takes China rights to novel antibiotic from Recida

U.S.-based Recida Therapeutics Inc., newly launched with backing from VC firm Frazier Healthcare Partners, announced it has licensed Greater China development and commercialization rights to a novel antibiotic to Sino-U.S. firm MicuRx Pharmaceuticals Inc. The product in focus is RC-01, a novel LpxC inhibitor for the treatment of multidrug-resistant gram-negative infections that Recida has in-licensed from Japan’s Fujifilm Toyama Chemical Co., Ltd. No financials were disclosed.

RC-01 is Recida’s first product and is set for an IND filing in the U.S. in Q1 2019. The drug has reportedly demonstrated bactericidal activity in pre-clinical testing against major clinically relevant pathogens such as the Enterobacteriaceae and Pseudomonas aeruginosa families of bacteria, and is also active in vitro against highly resistant P. aeruginosa samples from patients with cystic fibrosis.

Related news
Sino-U.S. firm MicuRx Pharmaceuticals Inc., announced receipt of clinical trial approval from China’s National Medical Products Administration (NMPA) for the novel anti-microbial agent MRX-4.
  • 1541397405839
  • China
  • Drug
Japan’s Fujifilm Corp., is set to hand over manufacturing and development rights to anti-influenza (flu) drug Avigan (favipiravir) to Chinese firm Zhejiang Hisun Pharmaceutical Co., Ltd. A memorandum has been signed by Fujifilm and Hisun, as well as the China-Japan Friendship Clinic and the National Engineering Research Center for Emergency Drugs.
China-based biotech Innovent Biologics and the Sino-US biotech MicuRx Pharmaceuticals Inc., have both made formal filings for initial public offering (IPO) listings on the Hong Kong Stock Exchange (HKSE).
Sino-U.S. firm MicuRx Pharmaceuticals Inc., announced backing of USD 5.2 million from the global partnership Combating Antibiotic Resistant Bacteria Accelerator (CARB-X) to enable Investigational New Drug (IND) filing and Phase I clinical development of the former's drug candidate MRX-8 (PMX-8).
U.S.-based MicuRx Pharmaceuticals Inc., announced that it has raised RMB 100 million (USD 14.4 million) via a private financing round.
Recent news
  • 1550364318605
  • China
作者:药疯 由于患病人口数量庞大、后续并发致残致死率高、经济负担重、疾病重视程度低等特点,一直以来,心脑血管疾病都是严重威胁人类生命健康的重要疾病。
  • 1550364307286
  • China
日前,美国FierceBiotech网站公布了年度15家医疗技术“猛”公司(Fierce 15)的榜单。
  • 1550364307125
  • China
  • 1550364305337
  • China
2019年2月16日 讯 /生物谷BIOON/ --最近,来自ITMO的科学家与国际同事合作,提出了新的靶向DNA的纳米机器,可用于癌症的基因治疗。
  • 1550364298943
  • China
2019年2月16日 讯 /生物谷BIOON/ --神奇材料石墨烯可以成为解锁下一代早期肺癌诊断的关键。
  • 1550364298851
  • China
2019年2月16日 讯 /生物谷BIOON/ --美国能源部橡树岭国家实验室的科学家在《Science》杂志上首次描述了使用电子显微镜直接识别纳米级氨基酸中的同位素而不损坏样品的结果。
  • 1550364298761
  • China
Analytics Snapshot

Understand market developments and maintain your competitive advantage.